IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University

Reuters

2025/11/07

IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University

IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus $(SLE)$ donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581201001"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581201001\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581201001?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581201001","market":"nz","top_or_hot":-1,"title":"IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a> donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-07 05:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology <a href=\"https://laohu8.com/S/ACR\">$(ACR)$</a> Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus <a href=\"https://laohu8.com/S/SLE\">$(SLE)$</a> donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"半新股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8bK3hQ:1","article_id":"2581201001","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581201001","pubTimestamp":1762463676,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology  Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus  donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology  Annual Meeting.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","INAB":"IN8bio, Inc."},"translate_title":"IN8BIO将INB-100 γ-δ T细胞疗法1期试验扩展至俄亥俄州立大学","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INAB":0.9},"content_text":"IN8BIO Expands Phase 1 INB-100 Gamma-Delta T Cell Therapy Trial to Ohio State University\n    \n\n        IN8bio Inc. has announced the expansion of its Phase 1 INB-100 clinical trial to The James Comprehensive Cancer Center at The Ohio State University, aiming to accelerate patient enrollment for this study of donor-derived, allogeneic gamma-delta (γδ) T cell therapy in patients with leukemias undergoing haploidentical stem cell transplantation. Additionally, the company presented new preclinical data on INB-619, a CD19-targeting γδ T cell engager, at the 2025 American College of Rheumatology $(ACR)$ Convergence Meeting. The preclinical results demonstrated that INB-619 achieved complete elimination of B cells in systemic lupus erythematosus $(SLE)$ donor models, with efficacy comparable to currently FDA-approved CD19 and CD20 engagers. Updated clinical data for INB-200/400 in newly diagnosed glioblastoma are planned to be presented at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IN8BIO Inc. published the original content used to generate this news brief on November 06, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}